Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Subscribe To Our Newsletter & Stay Updated
